EDAP TMS S.A. (EDAP)
NASDAQ: EDAP · Real-Time Price · USD
2.580
-0.140 (-5.15%)
At close: Feb 21, 2025, 4:00 PM
2.560
-0.020 (-0.78%)
After-hours: Feb 21, 2025, 4:00 PM EST
EDAP TMS Revenue
EDAP TMS had revenue of 13.10M EUR in the quarter ending September 30, 2024, with 11.60% growth. This brings the company's revenue in the last twelve months to 63.41M, up 12.17% year-over-year. In the year 2023, EDAP TMS had annual revenue of 60.42M with 9.64% growth.
Revenue (ttm)
63.41M EUR
Revenue Growth
+12.17%
P/S Ratio
1.35
Revenue / Employee
206,547 EUR
Employees
307
Market Cap
95.73M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 60.42M | 5.31M | 9.64% |
| Dec 31, 2022 | 55.11M | 11.04M | 25.06% |
| Dec 31, 2021 | 44.07M | 2.40M | 5.77% |
| Dec 31, 2020 | 41.66M | -3.25M | -7.24% |
| Dec 31, 2019 | 44.91M | 5.73M | 14.62% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
EDAP News
- 16 days ago - Cortechs.ai and EDAP Announce World's First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center - GlobeNewsWire
- 5 weeks ago - EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures - GlobeNewsWire
- 6 weeks ago - EDAP Appoints Joshua H. Levine to Board of Directors - GlobeNewsWire
- 6 weeks ago - EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology - GlobeNewsWire
- 2 months ago - Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer - GlobeNewsWire
- 3 months ago - EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating Endometriosis - GlobeNewsWire
- 3 months ago - EDAP TMS S.A. (EDAP) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewsWire